Literature DB >> 25154041

Iminoxyl radical-promoted dichotomous cyclizations: efficient oxyoximation and aminooximation of alkenes.

Xie-Xue Peng1, Yun-Jing Deng, Xiu-Long Yang, Lin Zhang, Wei Yu, Bing Han.   

Abstract

A novel iminoxyl radical-involved metal-free approach to vicinal oxyoximation and aminooximation of unactivated alkenes is developed. This method utilizes the dichotomous reactivity of the iminoxyl radical to furnish a general difunctionalization on alkenes using simple tert-butyl nitrite (TBN) as the iminoxyl radical initiator as well the carbon radical trap. By using this protocol, oxime featured 4,5-dihydroisoxazoles and cyclic nitrones were facilely prepared from β,γ- and γ,δ-unsaturated ketoximes, respectively.

Entities:  

Year:  2014        PMID: 25154041     DOI: 10.1021/ol502258n

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  4 in total

1.  Hypervalent iodine-mediated Ritter-type amidation of terminal alkenes: The synthesis of isoxazoline and pyrazoline cores.

Authors:  Sang Won Park; Soong-Hyun Kim; Jaeyoung Song; Ga Young Park; Darong Kim; Tae-Gyu Nam; Ki Bum Hong
Journal:  Beilstein J Org Chem       Date:  2018-05-11       Impact factor: 2.883

Review 2.  Oxime radicals: generation, properties and application in organic synthesis.

Authors:  Igor B Krylov; Stanislav A Paveliev; Alexander S Budnikov; Alexander O Terent'ev
Journal:  Beilstein J Org Chem       Date:  2020-06-05       Impact factor: 2.883

3.  Discovery and Biological Evaluation of CD147 N-Glycan Inhibitors: A New Direction in the Treatment of Tumor Metastasis.

Authors:  Wenqian Li; Daojiong Wang; Yushu Ge; Lei Zhang; Jiang Wu; Dan Liu
Journal:  Molecules       Date:  2020-12-23       Impact factor: 4.411

4.  Iminoxyl radicals vs. tert-butylperoxyl radical in competitive oxidative C-O coupling with β-dicarbonyl compounds. Oxime ether formation prevails over Kharasch peroxidation.

Authors:  I B Krylov; S A Paveliev; N S Shumakova; M A Syroeshkin; B N Shelimov; G I Nikishin; A O Terent'ev
Journal:  RSC Adv       Date:  2018-02-05       Impact factor: 3.361

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.